

## Odefsey<sup>®</sup> (emtricitabine/rilpivirine/tenofovir alafenamide) – Expanded indication

- On February 19, 2025, the FDA approved Gilead's [Odefsey \(emtricitabine/rilpivirine/tenofovir alafenamide\)](#), as a complete regimen for the **treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg**:
  - As initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL or
  - To replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey.
- Odefsey was previously approved for this indication in patients weighing at least 35 kg.
- Odefsey carries a boxed warning for post treatment acute exacerbation of hepatitis B.
- The recommended dosage of Odefsey is **one tablet taken orally once daily** with a meal in adults and pediatric patients with body weight at least 25 kg.
  - Odefsey is a three-drug fixed dose combination product containing 200 mg of emtricitabine, 25 mg of rilpivirine, and 25 mg of tenofovir alafenamide.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.